Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme Moyle

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2023
Switching to High Genetic Barrier Integrase Inhibitors Reduces Drug-Drug Interactions in People Living With HIVAra Askari, Chhavi Nashier, Rahul Ghelani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2009
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1Graeme Moyle, Edwin DeJesus, Marta Boffito, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2013
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokineticsGraeme Moyle, Laura Else, Akil Jackson, et al.
AIDS (London, England)|June 26, 2007
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceMarta Boffito, Alan Winston, Akil Jackson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal diseaseMelanie Hart, Alan Steel, Sally A Clark, et al.
Antiviral Therapy|January 30, 2003
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapyOle Kirk, Court Pedersen, Matthew Law, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2020
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokineticsEmilie R Elliot, Megan Neary, Laura Else, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjectsMarta Boffito, David Back, Meredith Stainsby-Tron, et al.
The Journal of Antimicrobial Chemotherapy|March 11, 2014
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteersAkil Jackson, Antonio D'Avolio, Graeme Moyle, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2023
Switching to High Genetic Barrier Integrase Inhibitors Reduces Drug-Drug Interactions in People Living With HIVAra Askari, Chhavi Nashier, Rahul Ghelani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2009
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1Graeme Moyle, Edwin DeJesus, Marta Boffito, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2013
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokineticsGraeme Moyle, Laura Else, Akil Jackson, et al.
AIDS (London, England)|June 26, 2007
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceMarta Boffito, Alan Winston, Akil Jackson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal diseaseMelanie Hart, Alan Steel, Sally A Clark, et al.
Antiviral Therapy|January 30, 2003
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapyOle Kirk, Court Pedersen, Matthew Law, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2020
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokineticsEmilie R Elliot, Megan Neary, Laura Else, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjectsMarta Boffito, David Back, Meredith Stainsby-Tron, et al.
The Journal of Antimicrobial Chemotherapy|March 11, 2014
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteersAkil Jackson, Antonio D'Avolio, Graeme Moyle, et al.
Pageof 12